Non-canonical peptides bound to MHC

Current Pharmaceutical Design

Volumn 15, Issue 28, 2009, Pages 3274-3282

  Day, Stephanie L ^a   Ramsland, Paul A ^a   Apostolopoulos, Vasso ^a  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

Author keywords

MHC class I; Non canonical peptides; Vaccine

Indexed keywords

FREUND ADJUVANT; GLYCOPEPTIDE; H2 ANTIGEN; HLA DQ8 ANTIGEN; INFLUENZA VIRUS HEMAGGLUTININ; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN 1; MYELIN BASIC PROTEIN; PEPTIDE VACCINE; SYNTHETIC PEPTIDE; T LYMPHOCYTE RECEPTOR; VIRUS ENVELOPE PROTEIN; VIRUS NUCLEOPROTEIN;

AMINO ACID COMPOSITION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CELIAC DISEASE; COVALENT BOND; CYTOTOXIC T LYMPHOCYTE; DRUG BINDING SITE; DRUG CONFORMATION; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STABILITY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROCESSING; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION; VACCINATION;

AMINO ACIDS; ANIMALS; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; PEPTIDES; PROTEIN BINDING; T-LYMPHOCYTES;

EID: 70449457813     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789105090     Document Type: Review

References (124)

1. McMahan RH, McWilliams JA, Jordan KR, Dow SW, Wilson DB, Slansky JE. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumour vaccines. J Clin Invest 2006; 116: 2543-2551
2. Huseby ES, Crawford F, White J, Marrack P, Kappler JW. Interface-disrupting amino acids establish specificity between T cell receptors and complexes of major histocompatibility complex and peptide. Nat Immunol 2006; 7: 1191-1199 (Pubitemid 44594315)
3. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987; 329: 506-512 (Pubitemid 17131093)
4. Zijlstra M, Bix M, Simister NE, Loring JM, Raulet DH, Jaenisch R. Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. Nature 1990; 344: 742-746
5. Koller BH, Marrack P, Kappler JW, Smithies O. Normal development of mice deficient in beta 2M, MHC class I proteins, and CD8+ T cells. Science 1990; 248: 1227-1230
6. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987; 329: 512-518
7. Garrett TP, Saper MA, Bjorkman PJ, Strominger JL, Wiley DC. Specificity pockets for the side chains of peptide antigens in HLA-Aw68. Nature 1989; 342: 692-696
8. Guo HC, Madden DR, Silver ML, Jardetzky TS, Gorga JC, Strominger JL, et al. Comparison of the P2 specificity pocket in three human histocompatibility antigens: HLA-A*6801, HLA-A* 0201, and HLA-B*2705. Proc Natl Acad Sci USA 1993; 90: 8053-8057 (Pubitemid 23260853)
9. Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 A resolution. J Mol Biol 1991; 219: 277-319.
10. Falk K, Rotzschke O, Stevanovic S, Jung G, Rammensee HG. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991; 351: 290-296 (Pubitemid 21896578)
11. Rammensee HG. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995; 7: 85-96.
12. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics 1995; 41: 178-228.
13. Udaka K, Wiesmuller KH, Kienle S, Jung G, Walden P. Decrypting the structure of major histocompatibility complex class I-restricted cytotoxic T lymphocyte epitopes with complex peptide libraries. J Exp Med 1995; 181: 2097-2108
14. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50: 213-219 (Pubitemid 30099526)
15. Suri A, Walters JJ, Levisetti MG, Gross ML, Unanue ER. Identification of naturally processed peptides bound to the class I MHC molecule H-2Kd of normal and TAP-deficient cells. Eur J Immunol 2006; 36: 544-557
16. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 1997; 159: 5211-5218 (Pubitemid 127470046)
17. Apostolopoulos V, Chelvanayagam G, Xing PX, McKenzie IF. Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules. J Immunol 1998; 161: 767-775 (Pubitemid 28323540)
18. Daser A, Urlaub H, Henklein P. HLA-B27 binding peptides derived from the 57 kD heat shock protein of Chlamydia trachomatis: novel insights into the peptide binding rules. Mol Immunol 1994; 31: 331-336 (Pubitemid 24118602)
19. Gao L, Walter J, Travers P, Stauss H, Chain BM. Tumour-associated E6 protein of human papillomavirus type 16 contains an unusual H-2Kb-restricted cytotoxic T cell epitope. J Immunol 1995; 155: 5519-5526
20. Mandelboim O, Bar-Haim E, Vadai E, Fridkin M, Eisenbach L. Identification of shared tumour-associated antigen peptides between two spontaneous lung carcinomas. J Immunol 1997; 159: 6030-6036 (Pubitemid 127471539)
21. Apostolopoulos V, Yu M, Corper AL, Li W, McKenzie IF, Teyton L, et al. Crystal structure of a non-canonical high affinity peptide complexed with MHC class I: a novel use of alternative anchors. J Mol Biol 2002; 318: 1307-1316 (Pubitemid 34753999)
22. Apostolopoulos V, Yu M, Corper AL, Teyton L, Pietersz GA, McKenzie IF, et al. Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design. J Mol Biol 2002; 318: 1293-1305 (Pubitemid 34753998)
23. Apostolopoulos V, McKenzie IF, Wilson IA. Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design. Front Biosci 2001; 6: D1311-20.
24. Apostolopoulos V, Yu M, McKenzie IF, Wilson IA. Structural implications for the design of molecular vaccines. Curr Opin Mol Ther 2000; 2: 29-36. (Pubitemid 30140202)
25. Stauss HJ, Davies H, Sadovnikova E, Chain B, Horowitz N, Sinclair C. Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus. Proc Natl Acad Sci USA 1992; 89: 7871-7875
26. Apostolopoulos V, Haurum JS, McKenzie IF. MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur J Immunol 1997; 27: 2579-2587 (Pubitemid 27453847)
27. Momburg F, Roelse J, Hammerling GJ, Neefjes JJ. Peptide size selection by the major histocompatibility complex-encoded peptide transporter. J Exp Med 1994; 179: 1613-1623 (Pubitemid 24129578)
28. Momburg F, Roelse J, Howard JC, Butcher GW, Hammerling GJ, Neefjes JJ. Selectivity of MHC-encoded peptide transporters from human, mouse and rat. Nature 1994; 367: 648-651 (Pubitemid 24067707)
29. Androlewicz MJ, Cresswell P. How selective is the transporter associated with antigen processing? Immunity 1996; 5: 1-5.
30. Schumacher TN, Kantesaria DV, Heemels MT, Ashton-Rickardt PG, Shepherd JC, Fruh K, Yang Y, Peterson PA, Tonegawa S, Ploegh HL. Peptide length and sequence specificity of the mouse TAP1/TAP2 translocator. J Exp Med 1994 179: 533-540 (Pubitemid 24058741)
31. Roelse J, Gromme M, Momburg F, Hammerling G, Neefjes J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J Exp Med 1994; 180: 1591-1597 (Pubitemid 24328551)
32. Madden DR. The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995; 13: 587-622.
33. Zhang W, Young AC, Imarai M, Nathenson SG, Sacchettini JC. Crystal structure of the major histocompatibility complex class I H-2Kb molecule containing a single viral peptide: implications for peptide binding and T-cell receptor recognition. Proc Natl Acad Sci USA 1992; 89: 8403-8407
34. Fremont DH, Matsumura M, Stura EA, Peterson PA, Wilson IA. Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb. Science 1992; 257: 919-927
35. Young AC, Zhang W, Sacchettini JC, Nathenson SG. The three-dimensional structure of H-2Db at 2.4 A resolution: implications for antigen-determinant selection. Cell 1994; 76: 39-50. (Pubitemid 2040167)
36. Madden DR, Garboczi DN, Wiley DC. The antigenic identity of peptide-MHC complexes: a comparison of the conformations of five viral peptides presented by HLA-A2. Cell 1993; 75: 693-708. (Pubitemid 23346368)
37. Madden DR, Gorga JC, Strominger JL, Wiley DC. The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation. Nature 1991; 353: 321-325
38. Silver ML, Guo HC, Strominger JL, Wiley DC. Atomic structure of a human MHC molecule presenting an influenza virus peptide. Nature 1992; 360: 367-369
39. Guo HC, Jardetzky TS, Garrett TP, Lane WS, Strominger JL, Wiley DC. Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. Nature 1992; 360: 364-366
40. Henderson RA, Michel H, Sakaguchi K, Shabanowitz J, Appella E, Hunt DF, et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation. Science 1992; 255: 1264-1266
41. Joyce S, Kuzushima K, Kepecs G, Angeletti RH, Nathenson SG. Characterization of an incompletely assembled major histocompatibility class I molecule (H-2Kb) associated with unusually long peptides: implications for antigen processing and presentation. Proc Natl Acad Sci USA 1994; 91: 4145-4149 (Pubitemid 24984894)
42. Urban RG, Chicz RM, Lane WS, Strominger JL, Rehm A, Kenter MJ, et al. A subset of HLA-B27 molecules contains peptides much longer than nonamers. Proc Natl Acad Sci USA 1994; 91: 1534-1538 (Pubitemid 24059047)
43. Horig H, Young AC, Papadopoulos NJ, DiLorenzo TP, Nathenson SG. Binding of longer peptides to the H-2Kb heterodimer is restricted to peptides extended at their C terminus: refinement of the inherent MHC class I peptide binding criteria. J Immunol 1999; 163: 4434-4441 (Pubitemid 29474512)
44. Stevens J, Wiesmuller KH, Walden P, Joly E. Peptide length preferences for rat and mouse MHC class I molecules using random peptide libraries. Eur J Immunol 1998; 28: 1272-1279 (Pubitemid 28156418)
45. Bouvier M, Wiley DC. Importance of peptide amino and carboxyl termini to the stability of MHC class I molecules. Science 1994; 265: 398-402. (Pubitemid 24259973)
46. Fremont DH, Stura EA, Matsumura M, Peterson PA, Wilson IA. Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove. Proc Natl Acad Sci USA 1995; 92: 2479-2483
47. Tynan FE, Burrows SR, Buckle AM, Clements CS, Borg NA, Miles JJ, et al. T cell receptor recognition of a 'super-bulged' major histocompatibility complex class I-bound peptide. Nat Immunol 2005; 6: 1114-1122
48. Stryhn A, Pedersen LO, Holm A, Buus S. Longer peptide can be accommodated in the MHC class I binding site by a protrusion mechanism. Eur J Immunol 2000; 30: 3089-3099 (Pubitemid 30846024)
49. Tynan FE, Reid HH, Kjer-Nielsen L, Miles JJ, Wilce MC, Kostenko L, et al. A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatibility complex class I molecule. Nat Immunol 2007; 8: 268-276 (Pubitemid 46745376)
50. Speir JA, Stevens J, Joly E, Butcher GW, Wilson IA. Two different, highly exposed, bulged structures for an unusually long peptide bound to rat MHC class I RT1-Aa. Immunity 2001; 14: 81-92. (Pubitemid 32144689)
51. Tynan FE, Borg NA, Miles JJ, Beddoe T, El-Hassen D, Silins SL, et al. High resolution structures of highly bulged viral epitopes bound to major histocompatibility complex class I. Implications for T-cell receptor engagement and T-cell immunodominance. J Biol Chem 2005; 280: 23900-23909 (Pubitemid 40884878)
52. Miles JJ, Elhassen D, Borg NA, Silins SL, Tynan FE, Burrows JM, et al. CTL recognition of a bulged viral peptide involves biased TCR selection. J Immunol 2005; 175: 3826-3834 (Pubitemid 41292043)
53. Green KJ, Miles JJ, Tellam J, van Zuylen WJ, Connolly G, Burrows SR. Potent T cell response to a class I-binding 13-mer viral epitope and the influence of HLA micropolymorphism in controlling epitope length. Eur J Immunol 2004; 34: 2510-2519 (Pubitemid 39302808)
54. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 2007; 179: 5033-5040
55. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 1996; 14: 930-938 (Pubitemid 26280936)
56. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci USA 1995; 92: 10128-10132
57. Gillanders WE, Hanson HL, Rubocki RJ, Hansen TH, Connolly JM. Class I-restricted cytotoxic T cell recognition of split peptide ligands. Int Immunol 1997; 9: 81-89
58. Reddehase MJ, Rothbard JB, Koszinowski UH. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature 1989; 337: 651-653
59. Glithero A, Tormo J, Doering K, Kojima M, Jones EY, Elliott T. The crystal structure of H-2D(b) complexed with a partial peptide epitope suggests a major histocompatibility complex class I assembly intermediate. J Biol Chem 2006; 281: 12699-12704 (Pubitemid 43855360)
60. Haurum JS, Arsequell G, Lellouch AC, Wong SY, Dwek RA, McMichael AJ, et al. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J Exp Med 1994; 180: 739-744 (Pubitemid 24224155)
61. Haurum JS, Tan L, Arsequell G, Frodsham P, Lellouch AC, Moss PA, et al. Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. Eur J Immunol 1995; 25: 3270-3276 (Pubitemid 26004928)
62. Haurum JS, Hoier IB, Arsequell G, Neisig A, Valencia G, Zeuthen J, et al. Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. J Exp Med 1999; 190: 145-150 (Pubitemid 29330132)
63. Kastrup IB, Stevanovic S, Arsequell G, Valencia G, Zeuthen J, Rammensee HG, et al. Lectin purified human class I MHC-derived peptides: evidence for presentation of glycopeptides in vivo. Tissue Antigens 2000; 56: 129-135 (Pubitemid 30621278)
64. Abdel-Motal UM, Berg L, Rosen A, Bengtsson M, Thorpe CJ, et al. Immunization with glycosylated Kb-binding peptides generates carbohydrate-specific, unrestricted cytotoxic T cells. Eur J Immunol 1996; 26: 544-551 (Pubitemid 26091381)
65. Speir JA, Abdel-Motal UM, Jondal M, Wilson IA. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 1999; 10: 51-61. (Pubitemid 29077383)
66. Glithero A, Tormo J, Haurum JS, Arsequell G, Valencia G, Edwards J, et al. Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity 1999; 10: 63-74. (Pubitemid 29077384)
67. Apostolopoulos V, Yuriev E, Ramsland PA, Halton J, Osinski C, Li W, et al. A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor. Proc Natl Acad Sci USA 2003; 100: 15029-15034 (Pubitemid 37518011)
68. Ninkovic T, Hanisch FG. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J Immunol 2007; 179: 2380-2388
69. Ninkovic T, Kinarsky L, Engelmann K, Pisarev V, Sherman S, Finn OJ, et al. Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes. Mol Immunol 2008; 11.
70. Mouritsen S, Meldal M, Christiansen-Brams I, Elsner H, Werdelin O. Attachment of oligosaccharides to peptide antigen profoundly affects binding to major histocompatibility complex class II molecules and peptide immunogenicity. Eur J Immunol 1994; 24: 1066-1072 (Pubitemid 24132237)
71. Gad M, Jensen T, Gagne R, Komba S, Daugaard S, Kroman N, et al O. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue. Eur J Immunol 2003; 33: 1624-1632 (Pubitemid 36790423)
72. Ostrov DA, Roden MM, Shi W, Palmieri E, Christianson GJ, Mendoza L, et al. How H13 histocompatibility peptides differing by a single methyl group and lacking conventional MHC binding anchor motifs determine self-nonself discrimination. J Immunol 2002; 168: 283-289 (Pubitemid 34014128)
73. Lazoura E, Lodding J, Farrugia W, Ramsland PA, Stevens JE, Wilson IA, et al. Enhanced class I binding and immune responses through anchor modification of the non-canonical tumour associated MUC1-8 peptide. Immunol 2006: 119; 306-316
74. Lazoura E, Lodding J, Farrugia W, Day S, Ramsland PA, Apostolopoulos V. Non-canonical anchor motif peptides bound to MHC class I induce cellular responses. Mol Immunol 2009: 46; 1171-1178
75. Marastoni M, Bazzaro M, Micheletti F, Gavioli R, Tomatis R. Peptide analogues of a subdominant epitope expressed in ebv-associated tumours: synthesis and immunological activity. J Med Chem 2001; 44: 2370-2373 (Pubitemid 32867406)
76. Marastoni M, Bazzaro M, Micheletti F, Gavioli R, Tomatis R. Cytotoxic T lymphocyte epitope analogues containing cis- or trans-4- aminocyclohexanecarboxylic acid residues. Bioorg Med Chem 2002; 10: 3061-3066 (Pubitemid 34761887)
77. Steer DL, Lew RA, Perlmutter P, Smith AI, Aguilar MI. Beta-amino acids: versatile peptidomimetics. Curr Med Chem 2002; 9: 811-822
78. Webb AI, Dunstone MA, Williamson NA, Price JD, de Kauwe A, Chen W, et al. T cell determinants incorporating beta-amino acid residues are protease resistant and remain immunogenic in vivo. J Immunol 2005; 175: 3810-3818 (Pubitemid 41292041)
79. Poenaru S, Lamas JR, Folkers G, Lopez de Castro JA, Seebach D, Rognan D. Nonapeptide analogues containing (R)-3-hydroxybutanoate and beta-homoalanine oligomers: synthesis and binding affinity to a class I major histocompatibility complex protein. J Med Chem 1999; 42: 2318-2331 (Pubitemid 29305165)
80. Guichard G, Zerbib A, Le Gal FA, Hoebeke J, Connan F, Choppin J, et al. Melanoma peptide MART-1(27-35) analogues with enhanced binding capacity to the human class I histocompatibility molecule HLA-A2 by introduction of a beta-amino acid residue: implications for recognition by tumour-infiltrating lymphocytes. J Med Chem 2000; 43: 3803-3808
81. Calbo S, Guichard G, Muller S, Kourilsky P, Briand JP, Abastado JP. Antitumour vaccination using a major histocompatibility complex (MHC) class I-restricted pseudopeptide with reduced peptide bond. J Immunother 2000; 23: 125-130 (Pubitemid 30079833)
82. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33-39 (Pubitemid 23233452)
83. Wolf PR, Ploegh HL. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol 1995; 11: 267-306.
84. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, et al. Predominant naturally processed peptides bound to HLADR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 1992; 358: 764-768
85. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA, Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991; 353: 622-627
86. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994; 368: 215-221 (Pubitemid 24108837)
87. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993; 178: 27-47. (Pubitemid 23173241)
88. Johansen BH, Vartdal F, Eriksen JA, Thorsby E, Sollid LM. Identification of a putative motif for binding of peptides to HLA-DQ2. Int Immunol 1996; 8: 177-182 (Pubitemid 26049769)
89. Kwok WW, Domeier ML, Raymond FC, Byers P, Nepom GT. Allele-specific motifs characterize HLA-DQ interactions with a diabetes-associated peptide derived from glutamic acid decarboxylase. J Immunol 1996; 156: 2171-2177 (Pubitemid 26087447)
90. Reizis B, Mor F, Eisenstein M, Schild H, Stefanovic S, Rammensee HG, et al. The peptide binding specificity of the MHC class II I-A molecule of the Lewis rat, RT1.BI. Int Immunol 1996; 8: 1825-1832 (Pubitemid 27007732)
91. Brown JH, Jardetzky T, Saper MA, Samraoui B, Bjorkman PJ, Wiley DC. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature 1988; 332: 845-850 (Pubitemid 18136876)
92. Sant'Angelo DB, Waterbury G, Preston-Hurlburt P, Yoon ST, Medzhitov R, Hong SC, et al. The specificity and orientation of a TCR to its peptide-MHC class II ligands. Immunity 1996; 4: 367-376 (Pubitemid 26174052)
93. Krieger JI, Karr RW, Grey HM, Yu WY, O'Sullivan D, Batovsky L, et al. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol 1991; 146: 2331-2340
94. Vignali DA, Strominger JL. Amino acid residues that flank core peptide epitopes and the extracellular domains of CD4 modulate differential signaling through the T cell receptor. J Exp Med 1994; 179: 1945-1956
95. Arnold PY, La Gruta NL, Miller T, Vignali KM, Adams PS, Woodland DL, et al. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol 2002; 169: 739-749 (Pubitemid 34753429)
96. Muller CP, Ammerlaan W, Fleckenstein B, Krauss S, Kalbacher H, Schneider F, et al. Activation of T cells by the ragged tail of MHC class II-presented peptides of the measles virus fusion protein. Int Immunol 1996; 8: 445-456 (Pubitemid 26115859)
97. Zavala-Ruiz Z, Strug I, Walker BD, Norris PJ, Stern LJ. A hairpin turn in a class II MHC-bound peptide orients residues outside the binding groove for T cell recognition. Proc Natl Acad Sci USA 2004; 101: 13279-13284 (Pubitemid 39209656)
98. Sercarz EE, Maverakis E. Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol 2003; 3: 621-629 (Pubitemid 37328665)
99. Golgher D, Korangy F, Gao B, Gorski K, Jaffee E, Edidin M, et al. An immunodominant MHC class II-restricted tumour antigen is conformation dependent and binds to the endoplasmic reticulum chaperone, calreticulin. J Immunol 2001; 167: 147-155 (Pubitemid 32567772)
100. Mimura Y, Mimura-Kimura Y, Doores K, Golgher D, Davis BG, Dwek RA, et al. Folding of an MHC class II-restricted tumour antigen controls its antigenicity via MHC-guided processing. Proc Natl Acad Sci USA 2007; 104: 5983-5988 (Pubitemid 47175645)
101. Lockey TD, Surman S, Brown S, Slobod KS, Coleclough C, Doherty PC, et al. A five-residue HIV envelope helper T cell determinant: does this peptide-MHC interaction leave the binding groove half empty? AIDS Res Hum Retroviruses 2002; 18: 1141-1144
102. Ertl HC, Dietzschold B, Otvos L, Jr. T helper cell epitope of rabies virus nucleoprotein defined by tri- and tetrapeptides. Eur J Immunol 1991; 21: 1-10.
103. Lundin KE, Scott H, Fausa O, Thorsby E, Sollid LM. T cells from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient preferentially recognize gliadin when presented by DQ8. Hum Immunol 1994; 41: 285-291
104. Lundin KE, Scott H, Hansen T, Paulsen G, Halstensen TS, Fausa O, et al. Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993; 178: 187-196 (Pubitemid 23173254)
105. van de Wal Y, Kooy YM, van Veelen PA, Pena SA, Mearin LM, Molberg O, et al. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci USA 1998; 95: 10050-10054 (Pubitemid 28415292)
106. van de Wal Y, Kooy Y, van Veelen P, Pena S, Mearin L, Papadopoulos G, et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998; 164: 1585-1588 (Pubitemid 28387571)
107. Molberg O, McAdam SN, Korner R, Quarsten H, Kristiansen C, Madsen L, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4: 713-717 (Pubitemid 28274673)
108. Hovhannisyan Z, Weiss A, Martin A, Wiesner M, Tollefsen S, Yoshida K, et al. The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature 2008; 456: 534-538 (Pubitemid 352759011)
109. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-1213
110. Michaelsson E, Broddefalk J, Engstrom A, Kihlberg J, Holmdahl R. Antigen processing and presentation of a naturally glycosylated protein elicits major histocompatibility complex class II-restricted, carbohydrate-specific T cells. Eur J Immunol 1996; 26: 1906-1910 (Pubitemid 26283168)
111. Corthay A, Backlund J, Broddefalk J, Michaelsson E, Goldschmidt TJ, Kihlberg J, et al. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur J Immunol 1998; 28: 2580-2590 (Pubitemid 28362732)
112. Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R. T cell recognition of carbohydrates on type II collagen. J Exp Med 1994; 180: 745-749 (Pubitemid 24224156)
113. Wooley PH, Luthra HS, Lafuse WP, Huse A, Stuart JM, David CS. Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera. J Immunol 1985; 134: 2366-2374
114. Brunsberg U, Gustafsson K, Jansson L, Michaelsson E, Ahrlund-Richter L, Pettersson S, et al. Expression of a transgenic class II Ab gene confers susceptibility to collagen-induced arthritis. Eur J Immunol 1997; 24: 1698-1702
115. Andersson IE, Dzhambazov B, Holmdahl R, Linusson A, Kihlberg J. Probing molecular interactions within class II MHC Aq/glycopeptide/T-cell receptor complexes associated with collagen-induced arthritis. J Med Chem 2007; 50: 5627-5643 (Pubitemid 350106018)
116. Holm L, Bockermann R, Wellner E, Backlund J, Holmdahl R, Kihlberg J. Side-chain and backbone amide bond requirements for glycopeptide stimulation of T-cells obtained in a mouse model for rheumatoid arthritis. Bioorg Med Chem 2006; 14: 5921-5932 (Pubitemid 44080584)
117. Tranquill LR, Cao L, Ling NC, Kalbacher H, Martin RM, Whitaker JN. Enhanced T cell responsiveness to citrulline-containing myelin basic protein in multiple sclerosis patients. Mult Scler 2000; 6: 220-225 (Pubitemid 30675985)
118. Matsuo K, Xiang Y, Nakamura H, Masuko K, Yudoh K, Noyori K, et al. Identification of novel citrullinated autoantigens of synovium in rheumatoid arthritis using a proteomic approach. Arthritis Res Ther 2006; 8: R175.
119. Martin R, Whitaker JN, Rhame L, Goodin RR, McFarland HF. Citrulline-containing myelin basic protein is recognized by T-cell lines derived from multiple sclerosis patients and healthy individuals. Neurology 1994; 44: 123-129 (Pubitemid 24029442)
120. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171: 538-541 (Pubitemid 36871358)
121. Deraos G, Chatzantoni K, Matsoukas MT, Tselios T, Deraos S, Katsara M, et al. Citrullination of linear and cyclic altered peptide ligands from myelin basic protein (MBP(87-99)) epitope elicits a Th1 polarized response by T cells isolated from multiple sclerosis patients: implications in triggering disease. J Med Chem 2008; 51: 7834-7842
122. Engelhardt B. The blood-central nervous system barriers actively control immune cell entry into the central nervous system. Curr Pharm Des 2008; 14(16): 1555-1565 (Pubitemid 352002983)
123. Louis CU, Brenner MK. Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics. Curr Pharm Des 2009; 15(4): 424-429
124. Yamin G, Ono K, Inayathullah M, Teplow DB. Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. Curr Pharm Des 2008; 14(30): 3231-3246